IDENTIFICATION OF WHICH FETAL GROWTH CHARTS AND BIRTHWEIGHT CENTILES ARE BEST ABLE TO IDENTIFY INFANTS AND MOTHERS AT RISK OF ADVERSE OBSTETRIC AND PERINATAL OUTCOMES
Grant number: 1150828 | Funding period: 2018 - 2023
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in mouse models and human tissue samples in the laboratory. This work may offer possibilities of new treatments to other pregnancy complications.
Related publications (3)
Nanoparticles in pregnancy: the next frontier in reproductive therapeutics
Natasha Pritchard, Tu'uhevaha Kaitu'u-Lino, Lynda Harris, Stephen Tong, Natalie Hannan
BACKGROUND: Nanotechnology involves the engineering of structures on a molecular level. Nanomedicine and nano-delivery systems hav..
Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction
Sally Beard, Natasha Pritchard, Natalie Binder, Karen Schindler, Natasha De Alwis, Tu'uhevaha J Kaitu'u-Lino, Stephen Tong, Natalie J Hannan
INTRODUCTION: Oxidative damage and biochemical ageing are implicated in placental dysfunction and potentially fetal death. Cellula..
ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia
Natasha Pritchard, Tu'uhevaha J Kaitu'u-Lino, Sungsam Gong, Justyna Dopierala, Gordon CS Smith, D Stephen Charnock-Jones, Stephen Tong
The genetic deletion of apelin receptor early endogenous ligand (Elabela; official name APELA) produces a preeclampsia-like phenot..